Abstract
Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Current Pharmaceutical Design
Title: Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy
Volume: 12 Issue: 13
Author(s): Sunil K. Nadar, Muzahir H. Tayebjee, Franz Messerli and Gregory Y.H. Lip
Affiliation:
Keywords: platelet activation, endothelial activation, target organ damage, Hypertension
Abstract: Hypertension is a well known risk factor for cardiovascular and cerebrovascular events such as heart attacks and strokes. In addition, it is associated with earlier changes in organ systems in the body, such as left ventricular hypertrophy (LVH), proteinuria and renal failure, retinopathy and vascular dementia which are grouped under the term "target organ damage"(TOD). There are many processes involved in the pathogenesis of TOD and these include endothelial activation, platelet activation, increased thrombogenesis, changes in the renin aldosterone angiotensin system (RAAS), and collagen turnover. All these changes work hand in hand and lead to the production of hypertensive TOD. In this review, we aim to provide an overview of the recent advances in pathophysiology of hypertensive TOD, and examine how these changes lead to the production of TOD. A better understanding of these pathogenic processes would help us better devise treatment strategies in preventing the dreaded complications associated with hypertension.
Export Options
About this article
Cite this article as:
Nadar K. Sunil, Tayebjee H. Muzahir, Messerli Franz and Lip Y.H. Gregory, Target Organ Damage in Hypertension: Pathophysiology and Implications for Drug Therapy, Current Pharmaceutical Design 2006; 12 (13) . https://dx.doi.org/10.2174/138161206776843368
DOI https://dx.doi.org/10.2174/138161206776843368 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitrite as a Physiological Source of Nitric Oxide and a Signalling Molecule in the Regulation of the Cardiovascular System in Both Mammalian and Non-Mammalian Vertebrates
Recent Patents on Cardiovascular Drug Discovery Central Hemodynamics for Risk Reduction Strategies: Additive Value Over and Above Brachial Blood Pressure
Current Pharmaceutical Design Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research VEGF Signaling in Cancer Treatment
Current Pharmaceutical Design Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Ca<sup>2+</sup>/Calmodulin-Dependent Protein Kinase- II in Vasoactive Peptide- Induced Responses and Vascular Biology
Current Vascular Pharmacology Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View
Current Diabetes Reviews New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Pharmaceutical Design Lifestyle Changes and Surgical Treatment for Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis of Benzothiazolyl Guanidinyl Derivatives and their In-Vitro Antimicrobial and Antioxidant Activity
The Natural Products Journal Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry What Characterizes Endothelial Dysfunction in Preeclampsia? -The Action of NO and the Production of Prostacyclin is Reduced, While EDHF is Preserved in Omental Resistance Arteries in Preeclamptic Women
Current Women`s Health Reviews Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism